Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119
Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target
BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs
Loading...